Skip to content
value.today

Inhibitex, Inc.

Total raised
$23 M
1 round on record
Latest round
$23 M
Oct 2009
First round on record
Oct 2009
Today
Private
No later event on record

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Inhibitex, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2009$23 MNo. 1$10 to $50 million

Inhibitex, Inc.: Raise no. 1, Oct 2009

Investors in this round

12 investors had bought by the notice of Nov 9, 2009: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$23 M of $23 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
$1 million to $5 million
Sales commissions
$1,200,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Geoffrey W. Henson · Executive Officer
  • Joseph M. Patti · Executive Officer
  • Russell H. Plumb · Executive Officer, Director
  • A. Keith L. Willard · Director
  • Chris M. McGuigan · Director
  • Gabriele M. Cerrone · Director
  • M. James M. Barrett · Director
  • Marc L. Preminger · Director
  • Michael M. Henos · Director
  • Russell M. Medord · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • MTS Securities, LLC (CRD 104059) · New York, NySold in no state named

Signed by Russell H. Plumb, President, CEO, CFO, Secretary, Treasurer and Director. Source: SEC Form D, newest notice filed Nov 9, 2009. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Inhibitex, Inc. had revenue between $1 million and $5 million when it filed its newest notice of a funding round (Nov 2009).

    SEC Form D (revenue range) · Nov 2009

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Nov 2009

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Inhibitex, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 12 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Inhibitex, Inc.
NameRoleNamed in
Geoffrey W. HensonExecutive officerNov 2009
Joseph M. PattiExecutive officerNov 2009
Russell H. PlumbExecutive officerNov 2009
A. Keith L. WillardDirectorNov 2009
Chris M. McGuiganDirectorNov 2009
Gabriele M. CerroneDirectorNov 2009
M. James M. BarrettDirectorNov 2009
Marc L. PremingerDirectorNov 2009
Michael M. HenosDirectorNov 2009
Russell H. PlumbDirectorNov 2009
Russell M. MedordDirectorNov 2009